Adalimumab in active ulcerative colitis: A “real-life” observational study

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

Sicurezza dell’Infliximab in bambini con malattia infiammatoria cronica intestinale (IBD): Registro pediatrico italiano di terapia biologica per le IBD. Studio multicentrico della società italiana di gastroenterologia, epatologia e nutrizione pediatrica (SIGENP).